Pricing Log in Create free account

Tempest Therapeutics, Inc. (TPST) vs VistaGen Therapeutics, Inc. (VTGN)

Tempest Therapeutics, Inc. and VistaGen Therapeutics, Inc. are both Biotechnology companies. Tempest Therapeutics, Inc. and VistaGen Therapeutics, Inc. are of similar size ($7.5M and $7.3M). VistaGen Therapeutics, Inc. grew revenue faster over the last twelve months: 287.2% against −53.0%. Tempest Therapeutics, Inc. has the higher net margin (0.00% vs −2,703.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, VistaGen Therapeutics, Inc. leads on 8 and Tempest Therapeutics, Inc. on 6.

Valuation

Metric TPST VTGN Biotechnology median
P/E n/m n/m 10.60
P/S 17.86 2.92 9.40
P/B n/m 0.30 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.23 0.66
EV/Sales 22.37 (6.44) 9.02
Earnings yield (1,178.26%) (976.47%) (32.88%)
Free cash flow yield (365.85%) (854.68%) (23.13%)

Profitability

Metric TPST VTGN Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (2,785.69%) 0.00%
Net margin 0.00% (2,703.72%) 0.00%
Free cash flow margin 0.00% (2,490.88%) 0.00%
Return on equity (931.14%) (166.46%) (51.96%)
Return on assets (237.25%) (129.22%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric TPST VTGN Biotechnology median
Revenue growth (TTM) (52.98%) 287.15% 6.76%
EPS growth (last fiscal year) 67.55% (9.58%) 29.88%
Revenue growth, 5-year CAGR — 3.10% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric TPST VTGN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.38 3.07 4.97
Net debt to EBITDA 0.29 0.63 1.01

Dividend

Metric TPST VTGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric TPST VTGN Biotechnology median
Market cap 7.50m 7.33m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack